Skip to main content
Fig. 1 | Genome Medicine

Fig. 1

From: Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models

Fig. 1

Flow chart and PDX bank characteristics. a Engraftment rate of 158 implanted patient tumor samples, frequencies for mutations associated with primary resistance to EGFR treatment from 105 PDX models analyzed by targeted NGS, and distribution of patient tumor stages of the 158 PDX models. PE, positive engraftment, NE, negative engraftment, RI, recently implanted. b Scheme for establishing the in vivo anti-EGFR SR PDX models and pre-testing targeted treatment option addressing molecular defined SR mechanisms. PD, progressive disease, SD stable disease, PR, partial response, CR, complete response. c Waterfall plot of cetuximab response after 3 weeks of treatment compared with tumor volume at baseline. Dotted lines indicate the cut-off values for progressive disease (PD) and partial response (PR). *,**,***, response at days 7, 15, and 31, respectively

Back to article page